Literature DB >> 12810640

Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.

Manon van Engeland1, Matty P Weijenberg, Guido M J M Roemen, Mirian Brink, Adriaan P de Bruïne, R Alexandra Goldbohm, Piet A van den Brandt, Stephen B Baylin, Anton F P M de Goeij, James G Herman.   

Abstract

Sporadic colorectal cancer (CRC) is characterized by genetic and epigenetic changes such as regional DNA hypermethylation and global DNA hypomethylation. Epidemiological and animal studies suggest that aberrant DNA methylation is associated with low dietary folate intake, which is aggravated by high alcohol intake. The relationship between promoter methylation of genes involved in CRC carcinogenesis and folate and alcohol intake was investigated. Methylation of the APC-1A, p14(ARF), p16(INK4A), hMLH1, O(6)-MGMT, and RASSF1A promoters was studied using methylation-specific PCR in 122 sporadic CRCs, derived from patients with folate and alcohol intake at either the lower or the higher quintiles of the distribution. Overall, promoter hypermethylation frequencies observed were: 39% for APC; 33% for p14(ARF); 31% for p16(INK4A); 29% for hMLH1; 41% for O(6)-MGMT; and 20% for RASSF1A. For each of the tested genes, the prevalence of promoter hypermethylation was higher in CRCs derived from patients with low folate/high alcohol intake (n = 61) when compared with CRCs from patients with high folate/low alcohol intake (n = 61), but the differences were not statistically significant. The number of CRCs with at least one gene methylated was higher (84%) in the low folate intake/high alcohol intake group when compared with the high folate intake/low alcohol intake group (70%; P = 0.085). Despite the size limitations of this study, these data suggest that folate and alcohol intake may be associated with changes in promoter hypermethylation in CRC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810640

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  98 in total

1.  Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.

Authors:  Milica Kontic; Jelena Stojsic; Dragana Jovanovic; Vera Bunjevacki; Simona Ognjanovic; Jacquelyn Kuriger; Susan Puumala; Heather H Nelson
Journal:  Clin Lung Cancer       Date:  2011-12-13       Impact factor: 4.785

Review 2.  DNA methylation and microRNAs in cancer.

Authors:  Xiang-Quan Li; Yuan-Yuan Guo; Wei De
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 3.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

Review 4.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

Review 5.  Prospects for epigenetic epidemiology.

Authors:  Debra L Foley; Jeffrey M Craig; Ruth Morley; Craig A Olsson; Craig J Olsson; Terence Dwyer; Katherine Smith; Richard Saffery
Journal:  Am J Epidemiol       Date:  2009-01-12       Impact factor: 4.897

6.  Folate levels in mucosal tissue but not methylenetetrahydrofolate reductase polymorphisms are associated with gastric carcinogenesis.

Authors:  Yu-Rong Weng; Dan-Feng Sun; Jing-Yuan Fang; Wei-Qi Gu; Hong-Yin Zhu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 7.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

8.  Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.

Authors:  Luca Morandi; Enrico Franceschi; Dario de Biase; Gianluca Marucci; Alicia Tosoni; Mario Ermani; Annalisa Pession; Giovanni Tallini; Alba Brandes
Journal:  BMC Cancer       Date:  2010-02-18       Impact factor: 4.430

Review 9.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

10.  Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Authors:  Alba A Brandes; A Tosoni; E Franceschi; V Blatt; A Santoro; M Faedi; P Amistà; M Gardiman; R Labianca; C Bianchini; M Ermani; M Reni
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.